Precision medicine in breast cancer: reality or utopia?

Journal of Translational Medicine

Review

François Ghiringhelli¹  Stéphanie Plenchette²  Catherine Paul²  Ali Bettaieb³  Jingxuan Shan⁴  Lotfi Chouchane⁴ 

[1] Département d’Oncologie Médicale, Centre Georges-François-Leclerc, 21000, Dijon, France;Plateforme de Transfert en Biologie Cancérologique, Centre Georges-François-Leclerc, 21000, Dijon, France;UMR 1231 Inserm-Université de Bourgogne Franche Comté, UFR des Sciences de Santé, 21000, Dijon, France;Université de Bourgogne, 21000, Dijon, France;Laboratoire d’Immunologie et Immunothérapie des Cancers, EPHE, PSL Research University, 75000, Paris, France;LIIC, EA7269, Université de Bourgogne Franche Comté, 21000, Dijon, France;Laboratoire d’Immunologie et Immunothérapie des Cancers, EPHE, PSL Research University, 75000, Paris, France;LIIC, EA7269, Université de Bourgogne Franche Comté, 21000, Dijon, France;Immunology and Immunotherapy of Cancer Laboratory, EA7269, Université de Bourgogne, EPHE 7 Bd Jeanne d’Arc, 21079, Dijon, France;Laboratory of Genetic Medicine and Immunology, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha, Qatar;

关键词: Breast cancer;    Molecular subtypes;    Triple-negative;    HER2+;    Tumor heterogeneity;    Precision medicine;    Chemotherapy;    Immunotherapy;    Phase III clinical trials;   

DOI  :  10.1186/s12967-017-1239-z

 received in 2017-03-27, accepted in 2017-06-09,  发布年份 2017

来源: Springer

【 摘 要 】

Many cancers, including breast cancer, have demonstrated prognosis and support advantages thanks to the discovery of targeted therapies. The advent of these new approaches marked the rise of precision medicine, which leads to improve the diagnosis, prognosis and treatment of cancer. Precision medicine takes into account the molecular and biological specificities of the patient and their tumors that will influence the treatment determined by physicians. This new era of medicine is accessible through molecular genetics platforms, the development of high-speed sequencers and means of analysis of these data. Despite the spectacular results in the treatment of cancers including breast cancer, described in this review, not all patients however can benefit from this new strategy. This seems to be related to the many genetic mutations, which may be different from one patient to another or within the same patient. It comes to give new impetus to the research—both from a technological and biological point of view—to make the hope of precision medicine accessible to all.

【 授权许可】

CC BY   
© The Author(s) 2017